BioN­Tech, Du­al­i­ty­Bio steer ADC in­to PhI­II, with aim to com­pete in HER2-low sub­group with En­her­tu

BioN­Tech is step­ping on As­traZeneca and Dai­ichi Sankyo’s turf with the launch of a Phase III tri­al for its an­ti­body-drug con­ju­gate aim­ing at a sub­set of breast can­cer pa­tients who his­tor­i­cal­ly have had few treat­ment op­tions.

The Ger­man biotech li­censed DB-1303, or BNT323, in April as part of a deal where it paid Chi­na’s Du­al­i­ty­Bio $170 mil­lion up­front. Like oth­er AD­Cs, it con­sists of an an­ti­body that homes in on the tar­get (in this case, HER2), a pay­load to kill the can­cer cells and a link­er to con­nect the two. Specif­i­cal­ly, it uti­lizes a topoi­so­merase-1 in­hibitor as the can­cer-killing pay­load.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER